Ankündigung • Apr 29
KBC Corporation, Ltd., Annual General Meeting, May 20, 2026 KBC Corporation, Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan China Ankündigung • Mar 30
KBC Corporation, Ltd. to Report Q1, 2026 Results on Apr 29, 2026 KBC Corporation, Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Reported Earnings • Mar 05
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: CN¥6.77 loss per share (further deteriorated from CN¥3.98 loss in FY 2024). Revenue: CN¥822.9m (up 53% from FY 2024). Net loss: CN¥1.38b (loss widened 70% from FY 2024). Revenue missed analyst estimates by 40%. Earnings per share (EPS) also missed analyst estimates significantly. Revenue is forecast to grow 62% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Ankündigung • Dec 26
KBC Corporation, Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 KBC Corporation, Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: CN¥0.53 loss per share (vs CN¥0.21 loss in 3Q 2024) Third quarter 2025 results: CN¥0.53 loss per share (further deteriorated from CN¥0.21 loss in 3Q 2024). Revenue: CN¥207.4m (up 113% from 3Q 2024). Net loss: CN¥107.8m (loss widened 152% from 3Q 2024). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Ankündigung • Sep 30
KBC Corporation, Ltd. to Report Q3, 2025 Results on Oct 30, 2025 KBC Corporation, Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 New Risk • Sep 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Price Target Changed • Sep 04
Price target increased by 12% to CN¥29.70 Up from CN¥26.47, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of CN¥30.90. Stock is up 96% over the past year. The company is forecast to post earnings per share of CN¥0.47 next year compared to a net loss per share of CN¥3.98 last year. Ankündigung • Jun 30
KBC Corporation, Ltd. to Report First Half, 2025 Results on Aug 29, 2025 KBC Corporation, Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Ankündigung • Apr 29
KBC Corporation, Ltd., Annual General Meeting, May 20, 2025 KBC Corporation, Ltd., Annual General Meeting, May 20, 2025, at 14:00 China Standard Time. Ankündigung • Mar 28
KBC Corporation, Ltd. to Report Q1, 2025 Results on Apr 29, 2025 KBC Corporation, Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 New Risk • Mar 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 02
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: CN¥3.79 loss per share (down from CN¥0.97 profit in FY 2023). Revenue: CN¥538.2m (down 50% from FY 2023). Net loss: CN¥775.8m (down 483% from profit in FY 2023). Revenue missed analyst estimates by 45%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Price Target Changed • Jan 17
Price target decreased by 9.9% to CN¥26.48 Down from CN¥29.40, the current price target is an average from 5 analysts. New target price is 30% above last closing price of CN¥20.37. Stock is down 50% over the past year. The company is forecast to post earnings per share of CN¥0.45 for next year compared to CN¥0.97 last year. Ankündigung • Dec 27
KBC Corporation, Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025 KBC Corporation, Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025 Price Target Changed • Dec 17
Price target increased by 9.1% to CN¥32.09 Up from CN¥29.40, the current price target is an average from 5 analysts. New target price is 38% above last closing price of CN¥23.19. Stock is down 42% over the past year. The company is forecast to post earnings per share of CN¥0.45 for next year compared to CN¥0.97 last year. Reported Earnings • Oct 30
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: CN¥0.21 loss per share (down from CN¥0.14 profit in 3Q 2023). Revenue: CN¥97.3m (down 64% from 3Q 2023). Net loss: CN¥42.8m (down 248% from profit in 3Q 2023). Revenue missed analyst estimates by 78%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 19 percentage points per year, which is a significant difference in performance. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Ankündigung • Sep 30
KBC Corporation, Ltd. to Report Q3, 2024 Results on Oct 30, 2024 KBC Corporation, Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Price Target Changed • Aug 31
Price target decreased by 7.2% to CN¥27.30 Down from CN¥29.40, the current price target is an average from 4 analysts. New target price is 71% above last closing price of CN¥15.93. Stock is down 71% over the past year. The company is forecast to post earnings per share of CN¥1.14 for next year compared to CN¥0.97 last year. Ankündigung • Aug 09
KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on August 6, 2024. KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on August 8, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on August 6, 2024. As per the mandate, the company is authorized to repurchase to repurchase CNY 20 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 35 per share. The shares repurchased will be used to reduce registered capital, used for employee stock ownership plan or equity incentive, used to convert company convertible bonds and to maintain company value and shareholder rights. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders, i.e., till September 5, 2024. Ankündigung • Jun 28
KBC Corporation, Ltd. to Report First Half, 2024 Results on Aug 30, 2024 KBC Corporation, Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Major Estimate Revision • May 30
Consensus EPS estimates fall by 27% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥1.88b to CN¥1.78b. EPS estimate also fell from CN¥2.31 per share to CN¥1.70 per share. Net income forecast to grow 852% next year vs 52% growth forecast for Chemicals industry in China. Consensus price target down from CN¥56.06 to CN¥43.81. Share price fell 4.8% to CN¥35.60 over the past week. Major Estimate Revision • May 09
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥1.90b to CN¥1.87b. EPS estimate also fell from CN¥2.84 per share to CN¥2.47 per share. Net income forecast to grow 1,505% next year vs 53% growth forecast for Chemicals industry in China. Consensus price target down from CN¥84.31 to CN¥69.31. Share price rose 5.7% to CN¥39.63 over the past week. Ankündigung • Apr 30
KBC Corporation, Ltd., Annual General Meeting, May 20, 2024 KBC Corporation, Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan China Reported Earnings • Apr 29
Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022) Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥202.5m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 65% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to CN¥39.48, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 63% over the past three years. Ankündigung • Mar 29
KBC Corporation, Ltd. to Report Q1, 2024 Results on Apr 29, 2024 KBC Corporation, Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024 Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥47.00, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 59% over the past three years. Ankündigung • Feb 27
KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on February 23, 2024. KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on February 26, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 23, 2023. As per the mandate, the company is authorized to repurchase to repurchase CNY 100 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 90 per share. The repurchased shares will be cancelled. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders. Reported Earnings • Feb 24
Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022) Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥203.3m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 31
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥45.84, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 69% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥88.65 per share. New Risk • Jan 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (41% accrual ratio). Buying Opportunity • Dec 08
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 6.6%. The fair value is estimated to be CN¥91.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 201% in 2 years. Earnings is forecast to grow by 156% in the next 2 years. New Risk • Nov 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (41% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Price Target Changed • Nov 04
Price target decreased by 8.9% to CN¥111 Down from CN¥122, the current price target is an average from 5 analysts. New target price is 45% above last closing price of CN¥76.50. Stock is down 57% over the past year. The company is forecast to post earnings per share of CN¥3.27 for next year compared to CN¥4.36 last year. Price Target Changed • Oct 27
Price target decreased by 7.7% to CN¥113 Down from CN¥122, the current price target is an average from 6 analysts. New target price is 35% above last closing price of CN¥83.20. Stock is down 47% over the past year. The company is forecast to post earnings per share of CN¥3.23 for next year compared to CN¥4.36 last year. Reported Earnings • Oct 24
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.98 in 3Q 2022). Revenue: CN¥271.1m (down 9.7% from 3Q 2022). Net income: CN¥28.8m (down 78% from 3Q 2022). Profit margin: 11% (down from 43% in 3Q 2022). Revenue missed analyst estimates by 46%. Earnings per share (EPS) also missed analyst estimates by 84%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Ankündigung • Sep 27
KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares. KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months. Major Estimate Revision • Aug 21
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥2.13b to CN¥2.06b. EPS estimate also fell from CN¥5.01 per share to CN¥4.36 per share. Net income forecast to grow 60% next year vs 52% growth forecast for Chemicals industry in China. Consensus price target down from CN¥137 to CN¥125. Share price fell 7.6% to CN¥91.68 over the past week. Reported Earnings • Aug 15
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: CN¥1.20 (down from CN¥1.39 in 2Q 2022). Revenue: CN¥304.6m (down 23% from 2Q 2022). Net income: CN¥165.1m (flat on 2Q 2022). Profit margin: 54% (up from 42% in 2Q 2022). Revenue missed analyst estimates by 24%. Earnings per share (EPS) also missed analyst estimates by 18%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Ankündigung • Jun 28
KBC Corporation, Ltd. to Report First Half, 2023 Results on Aug 29, 2023 KBC Corporation, Ltd. announced that they will report first half, 2023 results on Aug 29, 2023 New Risk • Jun 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Ankündigung • May 30
KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares. KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months. Major Estimate Revision • May 10
Consensus revenue estimates increase by 14%, EPS downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from CN¥1.85b to CN¥2.12b. EPS estimate fell from CN¥7.41 to CN¥7.19. Net income forecast to grow 61% next year vs 54% growth forecast for Chemicals industry in China. Consensus price target down from CN¥241 to CN¥218. Share price fell 9.0% to CN¥160 over the past week. Reported Earnings • Apr 22
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 9.2%. Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Reported Earnings • Mar 01
Full year 2022 earnings released: EPS: CN¥6.45 (vs CN¥6.26 in FY 2021) Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Price Target Changed • Nov 16
Price target decreased to CN¥306 Down from CN¥348, the current price target is an average from 2 analysts. New target price is 22% above last closing price of CN¥250. Stock is down 24% over the past year. The company is forecast to post earnings per share of CN¥7.11 for next year compared to CN¥6.26 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥265, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 23% over the past year. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥1.46 (vs CN¥1.63 in 3Q 2021) Third quarter 2022 results: EPS: CN¥1.46 (down from CN¥1.63 in 3Q 2021). Revenue: CN¥300.2m (down 20% from 3Q 2021). Net income: CN¥128.8m (down 1.3% from 3Q 2021). Profit margin: 43% (up from 35% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Ankündigung • Sep 16
KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 200 million worth of its shares. KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The program is valid for 6 months. Major Estimate Revision • Sep 02
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from CN¥8.07 to CN¥7.09 per share. Revenue forecast steady at CN¥1.80b. Net income forecast to grow 12% next year vs 39% growth forecast for Chemicals industry in China. Consensus price target of CN¥365 unchanged from last update. Share price fell 11% to CN¥284 over the past week. Reported Earnings • Aug 29
Second quarter 2022 earnings released: EPS: CN¥2.06 (vs CN¥1.58 in 2Q 2021) Second quarter 2022 results: EPS: CN¥2.06 (up from CN¥1.58 in 2Q 2021). Revenue: CN¥396.3m (up 27% from 2Q 2021). Net income: CN¥165.3m (up 30% from 2Q 2021). Profit margin: 42% (up from 41% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 26%, compared to a 40% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Aug 01
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥381, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 42% over the past year. Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥330, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 15% over the past year. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥272, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 37% over the past year. Price Target Changed • Jun 01
Price target decreased to CN¥365 Down from CN¥394, the current price target is an average from 3 analysts. New target price is 49% above last closing price of CN¥245. Stock is up 17% over the past year. The company is forecast to post earnings per share of CN¥8.07 for next year compared to CN¥6.26 last year. Valuation Update With 7 Day Price Move • May 02
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥214, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 15x in the Chemicals industry in China. Total returns to shareholders of 21% over the past year. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥2.53 (up from CN¥0.97 in 1Q 2021). Revenue: CN¥450.2m (up 126% from 1Q 2021). Net income: CN¥202.7m (up 163% from 1Q 2021). Profit margin: 45% (up from 39% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) also surpassed analyst estimates by 8.9%. Over the next year, revenue is forecast to grow 21%, compared to a 43% growth forecast for the industry in China. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Apr 26
KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares. KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program is valid for 2 months. Major Estimate Revision • Mar 15
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from CN¥2.02b to CN¥1.75b. EPS estimate unchanged from CN¥8.07 per share at last update. Chemicals industry in China expected to see average net income growth of 47% next year. Consensus price target of CN¥400 unchanged from last update. Share price rose 9.9% to CN¥238 over the past week. Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment deteriorated over the past week After last week's 23% share price decline to CN¥222, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 43% over the past year. Reported Earnings • Feb 27
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥6.26 (up from CN¥2.35 in FY 2020). Revenue: CN¥1.34b (up 214% from FY 2020). Net income: CN¥501.1m (up 197% from FY 2020). Profit margin: 38% (down from 40% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) also surpassed analyst estimates by 8.9%. Over the next year, revenue is forecast to grow 27%, compared to a 47% growth forecast for the industry in China. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥1.63 (vs CN¥0.59 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥375.9m (up 264% from 3Q 2020). Net income: CN¥130.4m (up 220% from 3Q 2020). Profit margin: 35% (down from 40% in 3Q 2020). The decrease in margin was driven by higher expenses. Price Target Changed • Aug 29
Price target increased to CN¥366 Up from CN¥266, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of CN¥374. Stock is up 258% over the past year. Reported Earnings • Aug 25
Second quarter 2021 earnings released: EPS CN¥1.58 (vs CN¥0.48 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥312.7m (up 234% from 2Q 2020). Net income: CN¥126.8m (up 294% from 2Q 2020). Profit margin: 41% (up from 34% in 2Q 2020). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥204, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 115% over the past year. Valuation Update With 7 Day Price Move • May 10
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥148, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Chemicals industry in China. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.97 (vs CN¥0.69 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥199.4m (up 118% from 1Q 2020). Net income: CN¥77.2m (up 87% from 1Q 2020). Profit margin: 39% (down from 45% in 1Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Apr 02
Full year 2020 earnings released: EPS CN¥2.35 (vs CN¥1.32 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥426.5m (up 78% from FY 2019). Net income: CN¥168.6m (up 117% from FY 2019). Profit margin: 40% (up from 32% in FY 2019). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥149, the stock is trading at a trailing P/E ratio of 63.5x, down from the previous P/E ratio of 77.5x. This compares to an average P/E of 36x in the Chemicals industry in China. Is New 90 Day High Low • Jan 22
New 90-day high: CN¥235 The company is up 103% from its price of CN¥116 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 23% over the same period. Is New 90 Day High Low • Dec 30
New 90-day high: CN¥222 The company is up 121% from its price of CN¥100 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. Is New 90 Day High Low • Dec 10
New 90-day high: CN¥126 The company is up 24% from its price of CN¥101 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 10.0% over the same period. Is New 90 Day High Low • Nov 04
New 90-day high: CN¥125 The company is up 19% from its price of CN¥105 on 06 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 3.0% over the same period. Ankündigung • Oct 19
KBC Corporation, Ltd. to Report Q3, 2020 Results on Oct 23, 2020 KBC Corporation, Ltd. announced that they will report Q3, 2020 results on Oct 23, 2020 Is New 90 Day High Low • Oct 12
New 90-day high: CN¥118 The company is up 15% from its price of CN¥102 on 14 July 2020. The Chinese market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 2.0% over the same period. Valuation Update With 7 Day Price Move • Oct 12
Market bids up stock over the past week After last week's 18% share price gain to CN¥118, the stock is trading at a trailing P/E ratio of 69.9x, up from the previous P/E ratio of 59.3x. This compares to an average P/E of 39x in the Chemicals industry in China. Ankündigung • Jul 06
KBC Corporation, Ltd. to Report First Half, 2020 Results on Aug 12, 2020 KBC Corporation, Ltd. announced that they will report first half, 2020 results on Aug 12, 2020